Investigational drug · Phase 2
GI-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GI-101"
First trial start
2021
Aug 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GI-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Cervical Cancer
- Urothelial Carcinoma
- Clear Cell Renal Cell Cancer (ccRCC)
- Squamous Cell Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Bladder and urothelial cancer · Cervical cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "GI-101" as an intervention, largest first.
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsPivotal-lookingRecruiting
GI Innovation, Inc.Industry
NCT04977453 · 317 participants (planned) · Start Aug 2, 2021 · Primary completion Jun 30, 2028
Drug: GI-101; Pembrolizumab (KEYTRUDA®) and 2 more · For: Advanced Solid Tumor; Metastatic Solid Tumor; Cervical Cancer and 3 more
Sites: New York, New York; Huntersville, North Carolina; Seoul, South Korea · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Erector Spinae Plane Block Versus Thoracic Paravertebral Block in Laparoscopic Cholecystectomy: A Randomized Controlled Study.
Turhan Ö, Sungur Z, Dinçer MB, et al. · J Clin Med 2026
- Exploration of antiproliferative potential of modified triazole-benzohydrazone scaffold: Multitarget approach.
Ali AM, Khalaf MA, Bhongade BA, et al. · Arch Pharm (Weinheim) 2024
- The Effects of Low- and High-Glycemic Index Sport Nutrition Bars on Metabolism and Performance in Recreational Soccer Players.
Kaviani M, Chilibeck PD, Gall S, et al. · Nutrients 2020
- Clinical and functional significance of α9β1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion.
Allen MD, Vaziri R, Green M, et al. · J Pathol 2011
- Predicting late effects of pelvic radiotherapy: is there a better approach?
Wedlake LJ, Thomas K, Lalji A, et al. · Int J Radiat Oncol Biol Phys 2010
- Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.
Guttery DS, Hancox RA, Mulligan KT, et al. · Breast Cancer Res 2010
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.